HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulation/Legislation (Health)

Set Alert for Regulation {Health}

Regulation

Set Alert for Regulation {Health}

Latest From Health & Regulation

Including Oxybenzone, Octinoxate On US Sunscreen Monograph Could Swing On Environmental Impact

FDA will prepare an environmental impact statement on sunscreen ingredients oxybenzone and octinoxate in light of questions on the ingredients’ impact on coral and coral reefs. It plans to complete the review prior to publishing final order for its OTC sunscreen ingredients monograph.

OTC Drugs FDA

Perrigo’s Latest Brand Buzz: Making, Marketing Burt’s Bees Baby Formula And Supplements

Perrigo’s brand play extends to marketing Burt’s Bees organic baby formulas and “nature-based” supplements for infants and children. Burt’s Bees announcement offsets Q1 dips in domestic and international consumer health sales.

OTC Drugs Sales & Earnings

People On The Move: Appointments At UPSA, Bionorica And MHRA

The latest European consumer health people news: Sanofi Consumer Healthcare's Van Rycke named CEO of UPSA; Bionorica's global business head steps down; MHRA names its first chief safety officer.

Appointments Leadership
See All

Legislation

Set Alert for Legislation {Health}

Latest From Health & Legislation

Including Oxybenzone, Octinoxate On US Sunscreen Monograph Could Swing On Environmental Impact

FDA will prepare an environmental impact statement on sunscreen ingredients oxybenzone and octinoxate in light of questions on the ingredients’ impact on coral and coral reefs. It plans to complete the review prior to publishing final order for its OTC sunscreen ingredients monograph.

OTC Drugs FDA

FTC Will Ask Congress To Sharpen Monetary Relief Authority Dulled By Supreme Court Ruling

Justice Breyer suggests FTC ask Congress to strengthen its enforcement rules. It is “free to ask Congress to grant it further remedial authority,” according to court opinion stating a rule the FTC has wielded for forty years to impose financial penalties doesn’t grant it authority to obtain equitable monetary relief.

Ad Complaints Legal Issues

Funding For US FDA Work On Cannabinoids Regulatory Pathway Drives Progress Only So Far

FDA is conducting lab testing on CBD products with funding in its FY2021 appropriations, says senior agency advisor Sharon Mayl. Some work planned work in the area has been delayed by the agency's response to COVID-19.

Cannabidiol CBD FDA
See All
UsernamePublicRestriction

Register